ADC Biotechnology

ADC Biotechnology is a biotech company that aims to expedite the development of anti-cancer drugs through innovative process technology. The company's slogan emphasizes its commitment to overcoming conjugation challenges and facilitating the production of ADC-based therapies. Founded in 2010, ADC Bio operates in the biopharma, biotechnology, and healthcare industries. In November 2018, the company received a significant £2.50M Venture Round investment from a consortium of investors, including Maven Capital Partners, Development Bank of Wales, Downing Ventures, and Seneca Partners. This funding is expected to fuel the company's efforts to streamline the development of ADC therapies, potentially advancing cancer treatment options. With its focus on addressing critical challenges in drug development, ADC Biotechnology is poised to make a meaningful impact in the healthcare industry.